Published:August 07, 2020DOI:
        Erratum to: Remon J, Passiglia F, Myung-Ju A, et al. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. J Thorac Oncol. 2020;15(6):914-947.
        Figure thumbnail fx1
        Figure 2Ongoing phase III trials with adjuvant immune checkpoint inhibitor (ICI). ACT, adjuvant chemotherapy; DFS, disease-free survival; ITT, intention to treat; OS, overall survival; PD-L1, programmed death ligand-1; PS, performance status; Q2W, every 2 weeks; Q3W, every 3 weeks; 1 y, 1 year.
        Table 3Ongoing clinical trials with neoadjuvant immune checkpoint inhibitors with or without chemotherapy

        MK3475-223NCT 02938624Pembrolizumab different dose / regimens → SI-II28IToxicity, MPR
        TOP 1501NCT 02818920Pembrolizumab (200 mg) x 2 cycles → S → Pembrolizumab (200 mg) x 4 cyclesIB-IIIA32IISurgical feasibility
        PRICNEPSNCT 02994576Atezolizumab (1200 mg) x 1 cycle → SIA-IIIA (no N2)60IIToxicity
        SAKK 16/14NCT 02572843CT x 2 → Durvalumab (750 mg) x 2 cycles → Durvalumab (750 mg) x 1 yearIIIA (N2)68IIEFS
        IONESCONCT 03030131Durvalumab (750 mg) Q2W x 3 cycles → SIB-II81IIR0 resection
        CANOPY NNCT 03968419Canakinumab or pembrolizumab (200 mg) or Canakinumab + Pembrolizumab x 2 cycles → SIB-IIIA110IIMPR
        KEYNOTE 617NCT 03425643CT + Pembrolizumab (200 mg) / placebo x 4 cycles → S → Pembrolizumab / Placebo x 13 cyclesIIB-IIIA786IIIEFS, OS
        CheckMate 816∗NCT 02998528CT + Nivolumab (360 mg) x 3 cycles → S vs.

        CT x 3 cycles → S
        IMpower 030NCT 03456063CT + Atezolizumab`(1200 mg) / placebo x 4 cycles → S → Atezolizumab / Placebo x 16 cyclesII-IIIB(cT3N2)374IIIMPR
        AEGEANNCT 03800134CT + Durvalumab (1500 mg) / Placebo Q3W x 4 cycles → S → Durvalumab / Placebo Q4W x 12 cyclesIIA-IIIB300IIIMPR

        Linked Article

        • Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations
          Journal of Thoracic OncologyVol. 15Issue 6
          • Preview
            In the past 10 years, a deeper understanding of the immune landscape of cancers, including immune evasion processes, has allowed the development of a new class of agents. The reactivation of host antitumor immune response offers the potential for long-term survival benefit in a portion of patients with thoracic malignancies. The advent of programmed cell death protein 1/programmed death ligand-1 immune checkpoint inhibitors (ICIs), both as single agents and in combination with chemotherapy, and more recently, the combination of ICI, anti–programmed cell death protein 1, and anticytotoxic T-lymphocyte antigen 4 antibody, have led to breakthrough therapeutic advances for patients with advanced NSCLC, and to a lesser extent, patients with SCLC.
          • Full-Text
          • PDF
          Open Archive